-

11:38:27 AM

ZNTL Stock News

ZNTL - Zentalis Pharmaceuticals Inc

06/06/23 6:00 AM

Nasdaq : ZNTL

Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability with no treatment-related

RHEA-AI

neutral

05/25/23 5:38 PM

Nasdaq : ZNTL

clinical trial

Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting

Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR of 35.7% and mPFS of 10.4 months in combination with carboplatin Patients with Cyclin E1+ tumors benefited

RHEA-AI

neutral

05/23/23 7:00 AM

Nasdaq : ZNTL

conferences

Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations

Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical

RHEA-AI

neutral

05/10/23 7:00 AM

Nasdaq : ZNTL

earnings

Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor, in 1H 2023 Positive Phase 1b azenosertib + chemotherapy clinical data in ovarian cancer to be presented ahead of original guidance at the

RHEA-AI

neutral

04/26/23 10:00 AM

Nasdaq : ZNTL

conferencesclinical trial

Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting

Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib Company also announces collaborations with Foundation Medicine and Roche

RHEA-AI

positive

04/17/23 9:00 AM

Nasdaq : ZNTL

clinical trial

Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023

Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy combination study, including data on CCNE1 amplification and / or Cyclin E1 expression, in the

RHEA-AI

neutral

03/01/23 7:00 AM

Nasdaq : ZNTL

earnings

Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates

On track to declare monotherapy RP2D for potentially first-in-class/best-in-class Wee1 inhibitor, azenosertib (ZN-c3), and provide program updates and potential paths to registration in 1H 2023 Pursuing Cyclin E1 as a patient enrichment strategy for azenosertib monotherapy in ovarian cancer; Cyclin

RHEA-AI

positive

02/13/23 7:00 AM

Nasdaq : ZNTL

management

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer

Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers,

RHEA-AI

very positive

02/01/23 5:00 PM

Nasdaq : ZNTL

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer,

RHEA-AI

very positive

02/01/23 7:01 AM

Nasdaq : ZNTL

conferences

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer,

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next